Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-REG OUTCOME: Empagliflozin CV Safety in T2DM
NCT01131676Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2010
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 42
01
Overview
A Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Jul 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01131676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131676.